Literature DB >> 27567227

Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease.

Handoo Rhee1, Keng Lim Ng2, Brian Wan-Chi Tse3, Mei-Chun Yeh3, Pamela J Russell3, Colleen Nelson3, Paul Thomas4, Hemamali Samaratunga5, Ian Vela6, Glenda Gobe7, Simon Wood2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27567227     DOI： 10.1016/j.pathol.2016.05.011

Source DB:  PubMed          Journal:  Pathology        ISSN： 0031-3025            Impact factor:   5.306


× No keyword cloud information.
  12 in total

1.  Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.

Authors:  Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

Review 2.  A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).

Authors:  Thomas Ahn; Matthew J Roberts; Aous Abduljabar; Andre Joshi; Marlon Perera; Handoo Rhee; Simon Wood; Ian Vela
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

Review 3.  Nanoscale Technologies in the Fight against COVID-19: From Innovative Nanomaterials to Computer-Aided Discovery of Potential Antiviral Plant-Derived Drugs.

Authors:  Nunzio Iraci; Carmelo Corsaro; Salvatore V Giofrè; Giulia Neri; Angela Maria Mezzasalma; Martina Vacalebre; Antonio Speciale; Antonina Saija; Francesco Cimino; Enza Fazio
Journal:  Biomolecules       Date:  2022-07-30

Review 4.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

5.  Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.

Authors:  Giuliano Morgantetti; Keng Lim Ng; Hemamali Samaratunga; Handoo Rhee; Glenda C Gobe; Simon T Wood
Journal:  Transl Androl Urol       Date:  2019-05

6.  Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.

Authors:  Shaojun Zhu; Nader Hirmas; Jeremie Calais; Matthias Eiber; Boris Hadaschik; Martin Stuschke; Ken Herrmann; Johannes Czernin; Amar U Kishan; Nicholas G Nickols; David Elashoff; Wolfgang P Fendler
Journal:  BMC Cancer       Date:  2021-05-07       Impact factor: 4.430

7.  Imaging tumour thrombus of clear cell renal cell carcinoma: FDG PET or PSMA PET? Direct in vivo comparison of two technologies.

Authors:  Seyedehpariya Saadat; Bibiana Tie; Simon Wood; Ian Vela; Handoo Rhee
Journal:  Urol Case Rep       Date:  2017-10-05

Review 8.  Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.

Authors:  Louise Emmett; Kathy Willowson; John Violet; Jane Shin; Ashley Blanksby; Jonathan Lee
Journal:  J Med Radiat Sci       Date:  2017-03

9.  Multi-Modal PET and MR Imaging in the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial in Vivo Testing of Target-Specific Radioligands.

Authors:  Gordon Winter; Andrea B F Koch; Jessica Löffler; Mika Lindén; Christoph Solbach; Alireza Abaei; Hao Li; Gerhard Glatting; Ambros J Beer; Volker Rasche
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

Review 10.  PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Authors:  M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-12       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.